Who buys ECOR (ECOR) stock?
ECOR stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Eidelman Virant Capital, SWM Advisors, State Street Corp, Marshall Wace LLP, and BlackRock Inc..
How much did (ECOR) raise in its IPO?
(ECOR) raised $64 million in an initial public offering on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities acted as the underwriters for the IPO and BTIG was co-manager.
Does electrocore Inc (ECOR) stock have an upside of 190%?
Ladenburg Thalmann has initiated coverage of ElectroCore Inc (NASDAQ: ECOR) with a Buy rating and $3 price target, implying an upside of around 190%.
How much did Sapphire invest in electrocore Inc (ECOR) stock?
In the U.S., Sapphire has clearance for the treatment and prevention of ElectroCore Inc (NASDAQ: ECOR) has priced underwritten public offering of 18 million shares at $1 per share, representing a discount of 32% from the last close price of $1.48 on Tuesday. The gross proceeds will be approximately $18 million.
Is Ecor stock a good buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: ECOR) stock is to Strong Buy ECOR stock.
Is Ecor a buy or sell?
electroCore has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Who owns Ecor?
AWM Investment Company, Inc.
What does Ecor company do?
electroCore (ECOR) is a commercial-stage bioelectronic medical device company, with a proprietary non-invasive vagus nerve stimulation, or nVNS, therapy. nVNS is a “bioelectronic medical therapy that modulates neurotransmi...
What is electro core?
electroCore is a developer and marketer of non-invasive vagus nerve stimulation devices for the treatment of pain. The Company's gammaCore nVNS device is approved for cluster headache, and recently received label expansion for PH and HC in adults.
Should I buy or sell electroCore stock right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last year. There are currently 3 buy ratings f...
What is electroCore's stock price forecast for 2022?
3 equities research analysts have issued 1 year target prices for electroCore's shares. Their forecasts range from $0.93 to $2.75. On average, they...
How has electroCore's stock price performed in 2022?
electroCore's stock was trading at $0.5825 at the start of the year. Since then, ECOR shares have decreased by 0.9% and is now trading at $0.5775....
Are investors shorting electroCore?
electroCore saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 1,480,000 shares, an increa...
When is electroCore's next earnings date?
electroCore is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for electroC...
How were electroCore's earnings last quarter?
electroCore, Inc. (NASDAQ:ECOR) announced its earnings results on Thursday, May, 5th. The company reported ($0.08) earnings per share for the quart...
What guidance has electroCore issued on next quarter's earnings?
electroCore updated its second quarter 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for t...
Who are electroCore's key executives?
electroCore's management team includes the following people: Mr. Daniel S. Goldberger , CEO & Director (Age 63, Pay $810.67k) ( LinkedIn Profile...
Who are some of electroCore's key competitors?
Some companies that are related to electroCore include Stereotaxis (STXS) , Hyperfine (HYPR) , FONAR (FONR) , Electromed (ELMD) , Electromed (...
Is electroCore Inc. stock A Buy?
electroCore Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
What is the price target for ECOR in 2021?
On Aug 10, 2021 "HC Wainwright" gave "$3.00" rating for ECOR. The price target was changed from $1.04 to 1.0% .
Is electrocore oversold?
electroCore Inc. is oversold on RSI14 (13). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.
Is RSI 14 oversold?
RSImin/max Values: [ 20 - 75 ] RSI14 is 13 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.
What is gammacore sapphire?
Health Canada has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products to prevent and treat migraine and cluster headache. GammaCore Sapphire will be distributed in Canada by RSK Medical Inc, under an exclusive distribution agreement announced in January this year. The initial term of the agreement is three years. In February this year, the FDA approved an expanded label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17. Earlier in March, Australia's regulatory authority approved the device for primary headache disorders. GammaCore non-invasive vagus nerve stimulator is a non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache. It utilizes mild electrical stimulation to the vagus nerve that passes through the skin. Price Action: ECOR shares are up 7.9% at $2.19 on the last check Monday. See more from BenzingaClick here for options trades from BenzingaInvitae Accelerates Personalized Oncology Testing With Genosity AcquisitionVir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 Infection© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
How long is GammaCore nVNS?
The initial term of the agreement is three years. In February this year, the FDA approved an expanded label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17. Earlier in March, Australia's regulatory authority approved the device for primary headache disorders.
Is GammaCore a vagus nerve stimulator?
Earlier in March, Australia's regulatory authority approved the device for primary headache disorders. GammaCore non-invasive vagus nerve stimulator is a non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache.
What is fair value in accounting?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Is investing risky?
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality...
Is it a major deal for a single insider to buy stock?
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
What's Happening With ECOR Stock Today?
electroCore, Inc. (ECOR) stock has gained 10.4% while the S&P 500 is lower by -0.1% as of 10:14 AM on Monday, Sep 27. ECOR is up $0.12 from the previous closing price of $1.16 on volume of 1,921,965 shares. Over the past year the S&P 500 is higher by 32.80% while ECOR is lower by -21.95%. ECOR lost -$0.41 per share in the over the last 12 months.
More About electroCore, Inc
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology.
